BioSpace News Archive

West Pharmaceutical Services, Inc. announced that it will unveil its new Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention, taking place in San Diego, CA from June 13-16, 2022.

OneOncology, the national platform for independent oncology practices, appointed Thomas Stricker, MD as Medical Director for Precision Medicine.

The subscription period begins in Spago Nanomedical AB’s rights issue of shares of up to SEK 61.8 million, as resolved by the Board with the support of the authorization received at the Annual General Meeting on May 18, 2022.

TLC BioSciences announced that it has entered a commercialization agreement with Endo International plc for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain.

Endo International plc announced that its subsidiary Endo Ventures Limited has executed an agreement with Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product.

ImmunoGen Inc. announced a multi-year collaboration to research novel, first-in-class ADCs with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, utilizing ImmunoGen’s proprietary linker-payload technology directed to novel targets identified via OBT’s proprietary OGAP® discovery platform.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, has initiated a study to evaluate shock wave therapy as a treatment for Exercised Induced Pulmonary Hemorrhage.

Plus Therapeutics, Inc. today announced it will present positive data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the Phase 1/2a ReSPECT™-GBM dose escalation clinical trial in patients with recurrent glioblastoma (GBM) during an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, on June 14 at 10:20 AM PT in Vancouver, British Columbia, Canada.

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD).

NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang , Ph.D., MBA, will present a company update at the upcoming BIO International Convention, to be held June 13-16 in San Diego, CA.